SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack in the Box is trending due to a high-conviction short squeeze thesis, with retail investors highlighting its small float and significant short interest relative to its available shares. Community members are actively debating the stock's potential for a massive move, frequently comparing its technical setup to other major short squeeze plays and weighing it against competitors in the fast-food sector.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors focus on the upcoming Vitreoretinal Benefit Society presentation and the potential for a swift NDA filing following strong Phase 3 superiority data for its wet AMD candidate. While the community is actively debating the company's regulatory path and the competitive landscape against standard anti-VEGF treatments, sentiments remain divided between those anticipating a buyout or breakthrough and those concerned by ongoing stock volatility.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit Inc. is attracting significant community attention as investors debate its role as an AI data licensing powerhouse, with many highlighting potential partnerships with major LLM providers as a long-term growth catalyst. Sentiment remains polarized, with retail bulls focusing on its unique data moat and institutional potential while others express frustration over persistent price volatility and the stock's tendency to trade in lockstep with broader software sector rotations.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is currently experiencing significant market momentum fueled by the launch of Ford Energy and strategic partnerships aimed at positioning the automaker within the grid-scale power and data center infrastructure sector. Community discussion is focused on the potential for long-term valuation rerating, with many traders analyzing institutional call option activity and upcoming product reveals as catalysts for continued upside.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is experiencing significant volatility as investors digest Phase 3 clinical data, which met primary efficacy endpoints but sparked safety concerns regarding potential malignancy risks. The community is actively debating whether these findings represent a genuine safety signal or statistical noise, while some participants view the sharp selloff as a strategic accumulation opportunity ahead of anticipated M&A activity.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant volatility and trading momentum as investors pivot their focus toward the company's expanding oncology pipeline and the upcoming FDA advisory committee vote on its mRNA-based influenza vaccine. Community sentiment remains deeply divided, with bulls highlighting the platform's long-term diversification strategy while bears focus on regulatory hurdles and the ongoing debate regarding mRNA technology.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is rallying following reports that the company plans to launch a cloud-computing division to monetize excess AI infrastructure, shifting investor perception from seeing its heavy capital expenditure as a pure cost toward a potential revenue-generating asset. Community sentiment is deeply divided, with bulls viewing this as a strategic ROI catalyst that justifies recent infrastructure investments, while bears remain skeptical, dismissing the move as a desperate mitigation strategy for overbuilt capacity and failed prior initiatives.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is facing significant downward pressure as investors rotate out of semiconductor stocks following a massive sector-wide rally and reports that Meta is considering monetizing excess AI compute capacity. Community discussion remains polarized, with many retail traders viewing the volatility as a routine accumulation opportunity and long-term buying window, while others express concern over softening AI infrastructure demand and potential competition from alternative memory suppliers.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is gaining traction following the announcement of a global Phase 3 clinical trial for its lead asset, aglatimagene, in patients with non-small cell lung cancer. The community is actively discussing this expansion as a major validation of the company's platform, with many investors highlighting the stock's potential amidst high short interest and upcoming BLA milestones.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing heightened volatility and intense community debate as participants weigh the impact of broader crypto market headwinds against potential speculative catalysts. While some investors are aggressively accumulating during price dips, others remain deeply skeptical, citing ongoing consolidation and lingering concerns over long-term utility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?

Key PointsThe chief medical officer of Monte Rosa Therapeutics reported selling 41,845 shares directly for a transaction value of approximately $882,000, based on a weighted average price of around $21.08 per share over June 23-24, 2026...

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -58.84% and -80.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-monte-rosa-therapeutics-inc-stock...

Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Expands By 18.2%

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totaling 15,837,633 shares...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating an...

Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 22.2%

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling...

Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $103,398.05 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) insider Philip Nickson sold 5,845 shares of the firm's stock in a transaction on Thursday, April 9th. The shares were sold at an average...

Philip Nickson Sells 5,845 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) insider Philip Nickson sold 5,845 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The shares were sold...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, Marketbeat...

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

GLUEMonte Rosa Therapeutics Inc

Fundamentals

Latest GLUE News